Return to the home page of D-is-for-Diabetes

Advertisement

 







 





Diabetes Information

SGLT2 Inhibitors

Editor's Note: This class of diabetes medications was not listed in NIH Publication No. 11-4222 October 2010, as they were not yet approved at that time.

Insert P

Brand Name Generic Name Approval Status
Forxiga (EU)
Farxiga (US)
dapagliflozin Approved in Europe, 2012
Approved in USA, 2014
Invokana canagliflozin Approved in USA, 2013
Jardiance empagliflozin Approved in Europe, 2014
Approved in USA, 2014

What does this medicine do?

SGLT2 Inhibitors (sodium-glucose co-transporter 2 inhibitors) help keep your blood glucose from going too high. They work by blocking the reabsorption of glucose by the kidney, increasing glucose excretion, and lowering blood glucose levels in diabetics who have elevated blood glucose levels.

What are the possible side effects?

The most common side effects of SGLT2 Inhibitors are vaginal yeast infection (vulvovaginal candidiasis) and urinary tract infection. Because these drugs are associated with a diuretic effect, they can cause a reduction in intravascular volume leading to orthostatic or postural hypotension (a sudden fall in blood pressure when standing up). This may result in symptoms such as dizziness or fainting, which are most common in the first three months of therapy.

Where can I find more information?

See:

        go to the top of this page

        go to the top of this page

Advertisement

Adapted from information provided by the FDA, at FDA approves Invokana to treat type 2 diabetes



 

Copyright ©

Go to the Copyright and Other Information page

This page was last updated at D-is-for-Diabetes on August 3, 2014

go to the top of this page go to home page read about us contact us read our disclaimer read our privacy policy search our website go to the site map find out what's new